Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKGWAH)

• Drug Name: MESULERGINE Drug Info
• Synonyms: Mesulergine; Mesulerginum; Mesulergina; Mesulergine [INN]; Mesulerginum [INN-Latin]; UNII-SML95FK06I; Mesulergina [INN-Spanish]; 64795-35-3; N'-(1,6-Dimethylergolin-8alpha-yl)-N,N-dimethylsulfamide; SML95FK06I; CQ 32085; CHEMBL12314; C18H26N4O2S; CHEBI:73378; 3-(1,6-Dimethyl-8alpha-ergolinyl)-1,1-dimethylsulfamid; NCGC00163168-01; DSSTox_RID_81540; DSSTox_CID_26324; DSSTox_GSID_46324; CU-32085; N'-[(8alpha)-1,6-dimethylergolin-8-yl]-N,N-dimethylsulfuric diamide; CAS-64795-35-3; AC1L2AKM; Biomol-NT_000077; AC1Q6V4R; GTPL206

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 68848
  ChEBI ID: CHEBI:73378
  CAS Number: CAS 64795-35-3
  TTD Drug ID: DMKGWAH

Molecule-Related Drug Atlas

Drug(s) Targeting Adenosine A3 receptor (ADORA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IB-MECA	DM9G5XD	Psoriasis vulgaris	EA90	Phase 3	[7]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[8]
NITD609	DMQHBSX	Malaria	1F40-1F45	Phase 2	[9]
CF102	DMP56WJ	Hepatocellular carcinoma	2C12.02	Phase 2	[10]
SCH-442416	DMQ2K1V	N. A.	N. A.	Phase 1	[11]
AST-004	DM5WMG7	Stroke	8B20	Phase 1	[12]
BEMESETRON	DMSPJX9	N. A.	N. A.	Discontinued in Phase 3	[4]
BAY 60-6583	DMTEJV1	Myocardial ischemia	BA6Z	Preclinical	[13]
CF602	DM0ULO2	Inflammation	1A00-CA43.1	Preclinical	[10]
CF502	DMQSJ20	Inflammation	1A00-CA43.1	Preclinical	[10]

Drug(s) Targeting 5-HT 3B receptor (HTR3B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BEMESETRON	DMSPJX9	N. A.	N. A.	Discontinued in Phase 3	[14]
SEROTONIN	DMOFCRY	Discovery agent	N.A.	Investigative	[15]
2-methyl-5-HT	DM1S5CB	N. A.	N. A.	Investigative	[16]
QUIPAZINE	DMPY6IG	Discovery agent	N.A.	Investigative	[15]
bilobalide	DM09Z35	Discovery agent	N.A.	Investigative	[17]
2-(4-Methyl-piperazin-1-yl)-quinoline	DMB8OY6	Discovery agent	N.A.	Investigative	[15]
BRL-24682	DMSB4EW	Discovery agent	N.A.	Investigative	[18]
6-(4-Methyl-piperazin-1-yl)-phenanthridine	DM1HAWR	Discovery agent	N.A.	Investigative	[15]
trichloroethanol	DMNALMF	Discovery agent	N.A.	Investigative	[19]
1-phenylbiguanide	DMA4XGL	Discovery agent	N.A.	Investigative	[20]

Drug(s) Targeting 5-HT 3A receptor (HTR3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dolasetron	DMMG26Z	Nausea	MD90	Approved	[21]
Alosetron	DML2A03	Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[22]
Tropisetron	DMNSJ7V	Fibromyalgia	MG30.01	Approved	[23]
Palonosetron	DMBHMOX	Nausea	MD90	Approved	[24]
Levetiracetam	DMTGDN8	Epilepsy	8A60-8A68	Approved	[23]
Procaine	DM4LSNE	Anaesthesia	9A78.6	Approved	[25]
Cilansetron	DMP0NGX	Irritable bowel syndrome	DD91.0	Phase 3	[26]
BEMESETRON	DMSPJX9	N. A.	N. A.	Discontinued in Phase 3	[14]
Norcisapride	DMJSKUI	Gastroesophageal reflux disease	DA22.Z	Discontinued in Phase 2	[27]
YM-114	DML2IXO	Nausea	MD90	Discontinued in Phase 2	[28]

Drug(s) Targeting 5-HT 7 receptor (HTR7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RP5063	DMKUE8O	Schizophrenia	6A20	Phase 2	[29]
JNJ-18038683	DMV1T59	Major depressive disorder	6A70.3	Phase 2	[30]
AVN-101	DMOGFNI	Cognitive impairment	6D71	Phase 2	[31]
ATI-9242	DM6GKMU	Schizophrenia	6A20	Phase 1	[32]
PMID30124346-Compound-34TABLE4	DM2G3VE	Attention deficit hyperactivity disorder	6A05.Z	Patented	[33]
PMID30124346-Compound-13TABLE4	DMHTJVA	Attention deficit hyperactivity disorder	6A05.Z	Patented	[33]
Carbamide derivative 2	DMW5GI3	N. A.	N. A.	Patented	[34]
4-oxadiazole derivative 1	DMWFHKR	N. A.	N. A.	Patented	[34]
SB-269970	DM8WTGA	Sleep-wake disorder	7A00-7B2Z	Terminated	[35]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	DMM9X0G	Discovery agent	N.A.	Investigative	[36]

Drug(s) Affected By 5-hydroxytryptamine receptor 7 (HTR7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[37]
Cyproheptadine	DM92AH3	Allergic rhinitis	CA08.0	Approved	[6]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[6]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[38]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[39]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[40]
PD-0325901	DM27D4J	Breast cancer	2C60-2C65	Phase 2	[41]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[42]
SL65.0472	DMU5RKC	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 2	[43]
SB-269970	DM8WTGA	Sleep-wake disorder	7A00-7B2Z	Terminated	[6]

Drug(s) Affected By 5-hydroxytryptamine receptor 2C (HTR2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[5]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[5]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[5]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[44]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[45]
Nortriptyline	DM4KDYJ	Depression	6A70-6A7Z	Approved	[46]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[47]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[48]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[49]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[50]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 3A receptor (HTR3A)	TTPC4TU	5HT3A_HUMAN	Inhibitor	[2]
5-HT 3B receptor (HTR3B)	TTR6K75	5HT3B_HUMAN	Inhibitor	[2]
5-HT 7 receptor (HTR7)	TTO9X1H	5HT7R_HUMAN	Inhibitor	[3]
Adenosine A3 receptor (ADORA3)	TTJFY5U	AA3R_HUMAN	Inhibitor	[4]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
5-hydroxytryptamine receptor 2C (HTR2C)	OT6H8DE0	5HT2C_HUMAN	Protein Interaction/Cellular Processes	[5]
5-hydroxytryptamine receptor 7 (HTR7)	OT44DEWB	5HT7R_HUMAN	Protein Interaction/Cellular Processes	[6]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 206).
• [2] Novel and highly potent 5-HT3 receptor agonists based on a pyrroloquinoxaline structure. J Med Chem. 1997 Oct 24;40(22):3670-8.
• [3] Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity. J Med Chem. 2009 Apr 23;52(8):2384-92.
• [4] 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
• [5] Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
• [6] Clozapine and other competitive antagonists reactivate risperidone-inactivated h5-HT7 receptors: radioligand binding and functional evidence for GPCR homodimer protomer interactions. Psychopharmacology (Berl). 2010 Dec;212(4):687-97. doi: 10.1007/s00213-010-2001-x. Epub 2010 Sep 9.
• [7] A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993 Dec 20;336(1):57-60.
• [8] 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
• [9] Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
• [10] 2011 Pipeline of Can-Fite BioPharm.
• [11] Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5690-4.
• [12] Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke. Stroke. 2022 Jan;53(1):238-248.
• [13] Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007 Sep;43(3):262-71.
• [14] Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships. J Med Chem. 1992 Jan 24;35(2):310-9.
• [15] Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy ... J Med Chem. 1999 May 6;42(9):1556-75.
• [16] The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature. 1999 Jan 28;397(6717):359-63.
• [17] Ginkgolide B and bilobalide block the pore of the 5-HT eceptor at a location that overlaps the picrotoxin binding site. Neuropharmacology. 2011 Feb-Mar;60(2-3):488-95.
• [18] Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotoni... J Med Chem. 2003 Feb 27;46(5):702-15.
• [19] Co-expression of the 5-HT(3B) subunit with the 5-HT(3A) receptor reduces alcohol sensitivity. Brain Res Mol Brain Res. 2005 Dec 14;142(2):146-50.
• [20] Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. Neuropharmacology. 2001 Aug;41(2):282-4.
• [21] Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, do... Lancet Oncol. 2009 Feb;10(2):115-24.
• [22] Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844.
• [23] Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
• [24] Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag. 2009 Feb;5(1):21-34.
• [25] Local anesthetics have different mechanisms and sites of action at recombinant 5-HT3 receptors. Reg Anesth Pain Med. 2007 Nov-Dec;32(6):462-70.
• [26] Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.Expert Opin Investig Drugs.2005 Feb;14(2):185-93.
• [27] mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5679-83.
• [28] Effect of serotonin (5-HT)3-receptor antagonists YM060, YM114 (KAE-393), ondansetron and granisetron on 5-HT4 receptors and gastric emptying in rodents. Jpn J Pharmacol. 1995 Nov;69(3):205-14.
• [29] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [30] Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity. Front Behav Neurosci. 2015 Jan 15;8:453.
• [31] AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016 May 25;53(2):583-620.
• [32] Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12.
• [33] 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
• [34] Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
• [35] [(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors. Br J Pharmacol. 2000 May;130(2):409-17.
• [36] Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
• [37] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [38] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [39] Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer. BMC Genomics. 2006 Apr 3;7:68. doi: 10.1186/1471-2164-7-68.
• [40] Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve. 2007 Sep;36(3):329-35. doi: 10.1002/mus.20871.
• [41] PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 2014 Oct 9;514(7521):247-51.
• [42] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [43] Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95.
• [44] Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11927-32. doi: 10.1073/pnas.0609752104. Epub 2007 Jul 2.
• [45] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [46] Downregulation of serotonin receptor subtypes by nortriptyline and adinazolam in major depressive disorder: neuroendocrine and platelet markers. Clin Neuropharmacol. 1993;16 Suppl 3:S19-31.
• [47] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [48] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [49] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [50] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.